umu.sePublications
Change search
Link to record
Permanent link

Direct link
BETA
Erlanson, Martin
Publications (10 of 25) Show all publications
Abdulla, M., Hollander, P., Pandzic, T., Mansouri, L., Ednersson, S. B., Andersson, P.-O., . . . Amini, R.-M. (2020). Cell-of-origin determined by both gene expression profiling and immunohistochemistry is the strongest predictor of survival in patients with diffuse large B-cell lymphoma. American Journal of Hematology, 95(1), 57-67
Open this publication in new window or tab >>Cell-of-origin determined by both gene expression profiling and immunohistochemistry is the strongest predictor of survival in patients with diffuse large B-cell lymphoma
Show others...
2020 (English)In: American Journal of Hematology, ISSN 0361-8609, E-ISSN 1096-8652, Vol. 95, no 1, p. 57-67Article in journal (Refereed) Published
Abstract [en]

The tumor cells in diffuse large B-cell lymphomas (DLBCL) are considered to originate from germinal center derived B-cells (GCB) or activated B-cells (ABC). Gene expression profiling (GEP) is preferably used to determine the cell of origin (COO). However, GEP is not widely applied in clinical practice and consequently, several algorithms based on immunohistochemistry (IHC) have been developed. Our aim was to evaluate the concordance of COO assignment between the Lymph2Cx GEP assay and the IHC-based Hans algorithm, to decide which model is the best survival predictor. Both GEP and IHC were performed in 359 homogenously treated Swedish and Danish DLBCL patients, in a retrospective multicenter cohort. The overall concordance between GEP and IHC algorithm was 72%; GEP classified 85% of cases assigned as GCB by IHC, as GCB, while 58% classified as non-GCB by IHC, were categorized as ABC by GEP. There were significant survival differences (overall survival and progression-free survival) if cases were classified by GEP, whereas if cases were categorized by IHC only progression-free survival differed significantly. Importantly, patients assigned as non-GCB/ABC both by IHC and GEP had the worst prognosis, which was also significant in multivariate analyses. Double expression of MYC and BCL2 was more common in ABC cases and was associated with a dismal outcome. In conclusion, to determine COO both by IHC and GEP is the strongest outcome predictor to identify DLBCL patients with the worst outcome.

Place, publisher, year, edition, pages
Wiley-Blackwell, 2020
National Category
Hematology
Identifiers
urn:nbn:se:umu:diva-165343 (URN)10.1002/ajh.25666 (DOI)000495085000001 ()31659781 (PubMedID)
Funder
Swedish Cancer SocietySwedish Research CouncilVästerbotten County Council
Available from: 2019-11-26 Created: 2019-11-26 Last updated: 2020-03-23Bibliographically approved
Lagerlöf, I., Holte, H., Glimelius, I., Björkholm, M., Enblad, G., Erlanson, M., . . . Molin, D. (2020). No excess long-term mortality in stage I-IIA Hodgkin lymphoma patients treated with ABVD and limited field radiotherapy. British Journal of Haematology, 188(5), 685-691
Open this publication in new window or tab >>No excess long-term mortality in stage I-IIA Hodgkin lymphoma patients treated with ABVD and limited field radiotherapy
Show others...
2020 (English)In: British Journal of Haematology, ISSN 0007-1048, E-ISSN 1365-2141, Vol. 188, no 5, p. 685-691Article in journal (Refereed) Published
Abstract [en]

When treating limited stage classical Hodgkin lymphoma (cHL), balancing treatment efficacy and toxicity is important. Toxicities after extended-field radiotherapy are well documented. Investigators have aimed at reducing toxicity without compromising efficacy, mainly by using combined modality treatment (CMT), i.e. chemotherapy and limited-field radiotherapy. In some clinical trials, radiotherapy has been omitted. We evaluated 364 patients with stage I-IIA cHL treated between 1999 and 2005. Patients were treated with two or four cycles of doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) according to presence of risk factors, followed by 30 Gy limited-field (reduced compared to involved-field) radiotherapy. After a median follow-up of 16 years for survival, freedom from progression at five and ten years was 93% and overall survival at 5 and 10 years was 98% and 96%, respectively. Only two relapses, out of 27, occurred after more than 5 years. There was no excess mortality compared to the general population. Of the analysed subgroups, only patients with progression within five years showed significant excess mortality. The absence of excess mortality questions the concept of omitting radiotherapy after short-term chemotherapy, a strategy that has been associated with an elevated risk of relapse but not yet with a proven reduced long-term excess mortality.

Place, publisher, year, edition, pages
John Wiley & Sons, 2020
Keywords
limited stage, hodgkin lymphoma, relative survival
National Category
Hematology
Identifiers
urn:nbn:se:umu:diva-169098 (URN)10.1111/bjh.16232 (DOI)000516520300015 ()31612478 (PubMedID)
Available from: 2020-03-20 Created: 2020-03-20 Last updated: 2020-03-20Bibliographically approved
Ghez, D., Fortpied, C., Mounier, N., Carde, P., Perrot, A., Khaled, H., . . . Ferme, C. (2017). First-line escalated BEACOPP does not hinder stem cell collection and transplantation strategy in patients with relapsed/refractory Hodgkin's lymphoma [Letter to the editor]. Bone Marrow Transplantation, 52(2), 310-312
Open this publication in new window or tab >>First-line escalated BEACOPP does not hinder stem cell collection and transplantation strategy in patients with relapsed/refractory Hodgkin's lymphoma
Show others...
2017 (English)In: Bone Marrow Transplantation, ISSN 0268-3369, E-ISSN 1476-5365, Vol. 52, no 2, p. 310-312Article in journal, Letter (Refereed) Published
Place, publisher, year, edition, pages
NATURE PUBLISHING GROUP, 2017
National Category
Cancer and Oncology
Identifiers
urn:nbn:se:umu:diva-133455 (URN)10.1038/bmt.2016.271 (DOI)000394134300025 ()27892946 (PubMedID)
Available from: 2017-04-12 Created: 2017-04-12 Last updated: 2018-06-09Bibliographically approved
Mansouri, L., Noerenberg, D., Young, E., Mylonas, E., Abdulla, M., Frick, M., . . . Damm, F. (2016). Frequent NFKBIE deletions are associated with poor outcome in primary mediastinal B-cell lymphoma. Blood, 128(23), 2666-2670
Open this publication in new window or tab >>Frequent NFKBIE deletions are associated with poor outcome in primary mediastinal B-cell lymphoma
Show others...
2016 (English)In: Blood, ISSN 0006-4971, E-ISSN 1528-0020, Vol. 128, no 23, p. 2666-2670Article in journal (Refereed) Published
Abstract [en]

We recently reported a truncating deletion in the NFKBIE gene, which encodes IkB epsilon, a negative feedback regulator of NF-kB, in clinically aggressive chronic lymphocytic leukemia (CLL). Because preliminary data indicate enrichment of NFKBIE aberrations in other lymphoid malignancies, we screened a large patient cohort (n = 1460) diagnosed with different lymphoid neoplasms. While NFKBIE deletions were infrequent in follicular lymphoma, splenic marginal zone lymphoma, and T-cell acute lymphoblastic leukemia (< 2%), slightly higher frequencies were seen in diffuse large B- cell lymphoma, mantle cell lymphoma, and primary central nervous system lymphoma (3% to 4%). In contrast, a remarkably high frequency of NFKBIE aberrations (46/203 cases [22.7%]) was observed in primary mediastinal B-cell lymphoma (PMBL) and Hodgkin lymphoma (3/11 cases [27.3%]). NFKBIE-deleted PMBL patients were more often therapy refractory (P =.022) and displayed inferior outcome compared with wild- type patients (5-year survival, 59% vs 78%; P = .034); however, they appeared to benefit from radiotherapy P = .022) and rituximab-containing regimens (P = .074). NFKBIE aberrations remained an independent factor in multivariate analysis (P =.003) and when restricting the analysis to immunochemotherapy-treated patients (P = .008). Whole-exome sequencing and gene expression profiling verified the importance of NF-kB deregulation in PMBL. In summary, we identify NFKBIE aberrations as a common genetic event across B-cell malignancies and highlight NFKBIE deletions as a novel poor-prognostic marker in PMBL.

National Category
Cancer and Oncology Cell and Molecular Biology
Identifiers
urn:nbn:se:umu:diva-131885 (URN)10.1182/blood-2016-03-704528 (DOI)000392652300015 ()27670424 (PubMedID)
Available from: 2017-02-24 Created: 2017-02-24 Last updated: 2018-11-14Bibliographically approved
Ghez, D., Fortpied, C., Mounier, N., Carde, P., Perrot, A., Khaled, H., . . . Ferme, C. (2016). STEM CELL COLLECTION AFTER FAILURE OF UPFRONT ABVD OR BEACOPP IN PATIENTS WITH HIGH RISK ADVANCED STAGE III-IV HODGKIN'S LYMPHOMA. Paper presented at 10th International Symposium on Hodgkin Lymphoma, Cologne, GERMANY, OCT 22-25, 2016. Haematologica, 101(S5), 50-50, Article ID P091.
Open this publication in new window or tab >>STEM CELL COLLECTION AFTER FAILURE OF UPFRONT ABVD OR BEACOPP IN PATIENTS WITH HIGH RISK ADVANCED STAGE III-IV HODGKIN'S LYMPHOMA
Show others...
2016 (English)In: Haematologica, ISSN 0390-6078, E-ISSN 1592-8721, Vol. 101, no S5, p. 50-50, article id P091Article in journal, Meeting abstract (Refereed) Published
National Category
Hematology
Identifiers
urn:nbn:se:umu:diva-131669 (URN)000392549000117 ()
Conference
10th International Symposium on Hodgkin Lymphoma, Cologne, GERMANY, OCT 22-25, 2016
Note

Supplement: 5, Meeting Abstract: P091

Available from: 2017-02-23 Created: 2017-02-23 Last updated: 2018-06-09Bibliographically approved
Junlen, H. R., Peterson, S., Kimby, E., Lockmer, S., Linden, O., Nilsson-Ehle, H., . . . Wahlin, B. E. (2015). Follicular lymphoma in Sweden: nationwide improved survival in the rituximab era, particularly in elderly women: a Swedish Lymphoma Registry Study. Leukemia, 29(3), 668-676
Open this publication in new window or tab >>Follicular lymphoma in Sweden: nationwide improved survival in the rituximab era, particularly in elderly women: a Swedish Lymphoma Registry Study
Show others...
2015 (English)In: Leukemia, ISSN 0887-6924, E-ISSN 1476-5551, Vol. 29, no 3, p. 668-676Article in journal (Refereed) Published
Abstract [en]

Treatment for follicular lymphoma (FL) improved with rituximab. In Sweden, first-line rituximab was gradually introduced between 2003 and 2007, with regional differences. The first national guidelines for FL were published in November 2007, recommending rituximab in first-line therapy. Using the population-based Swedish Lymphoma Registry, 2641 patients diagnosed with FL from 2000 to 2010 were identified and characterized by year and region of diagnosis, age (median, 65 years), gender (50% men), first-line therapy and clinical risk factors. Overall and relative survivals were estimated by calendar periods (2000-2002, 2003-2007 and 2008-2010) and region of diagnosis. With each period, first-line rituximab use and survival increased. Survival was superior in regions where rituximab was quickly adopted and inferior where slowly adopted. These differences were independent in multivariable analyses. Ten-year relative survival for patients diagnosed 2003-2010 was 92%, 83%, 78% and 64% in the age groups 18-49, 50-59, 60-69 and. 70, respectively. With increasing rituximab use, male sex emerged as an adverse factor. Survival improved in all patient categories, particularly in elderly women. The introduction and the establishment of rituximab have led to a nationwide improvement in FL survival. However, rituximab might be inadequately dosed in younger women and men of all ages.

National Category
Cancer and Oncology
Identifiers
urn:nbn:se:umu:diva-102466 (URN)10.1038/leu.2014.251 (DOI)000350734300016 ()25151959 (PubMedID)
Available from: 2015-05-19 Created: 2015-04-26 Last updated: 2018-06-07Bibliographically approved
Kolstad, A., Madsbu, U., Dahle, J., Stokke, C., Bach-Gansmo, T., Londalen, A. M., . . . Holte, H. (2014). A Phase I Study of (177)lu-DOTA-HH1 (Betalutin) Radioimmunotherapy for Patients with Relapsed CD37+Non-Hodgkin's B Cell Lymphoma. Blood, 124(21)
Open this publication in new window or tab >>A Phase I Study of (177)lu-DOTA-HH1 (Betalutin) Radioimmunotherapy for Patients with Relapsed CD37+Non-Hodgkin's B Cell Lymphoma
Show others...
2014 (English)In: Blood, ISSN 0006-4971, E-ISSN 1528-0020, Vol. 124, no 21Article in journal, Meeting abstract (Other academic) Published
National Category
Cancer and Oncology
Identifiers
urn:nbn:se:umu:diva-101419 (URN)000349242702165 ()
Available from: 2015-04-29 Created: 2015-03-30 Last updated: 2018-06-07Bibliographically approved
Junlen, H. R., Peterson, S., Kimby, E., Lockmer, S., Linden, O., Nilsson-Ehle, H., . . . Wahlin, B. E. (2014). Follicular Lymphoma Survival in Sweden in the Rituximab Era. Paper presented at 56th ASH Annual Meeting & Exposition, December 6-9, 2015, San Francisco, FL. Blood, 124(21)
Open this publication in new window or tab >>Follicular Lymphoma Survival in Sweden in the Rituximab Era
Show others...
2014 (English)In: Blood, ISSN 0006-4971, E-ISSN 1528-0020, Vol. 124, no 21Article in journal, Meeting abstract (Other academic) Published
National Category
Cancer and Oncology
Identifiers
urn:nbn:se:umu:diva-101422 (URN)000349242701039 ()
Conference
56th ASH Annual Meeting & Exposition, December 6-9, 2015, San Francisco, FL
Available from: 2015-04-02 Created: 2015-03-30 Last updated: 2018-06-07Bibliographically approved
Holte, H., Leppa, S., Bjorkholm, M., Fluge, O., Jyrkkio, S., Delabie, J., . . . Eriksson, M. (2013). Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Group study. Annals of Oncology, 24(5), 1385-1392
Open this publication in new window or tab >>Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Group study
Show others...
2013 (English)In: Annals of Oncology, ISSN 0923-7534, E-ISSN 1569-8041, Vol. 24, no 5, p. 1385-1392Article in journal (Refereed) Published
Abstract [en]

Background: Many patients with aggressive B-cell lymphomas and high clinical risk score still die of lymphoma after conventional R-CHOP chemoimmunotherapy. We hypothesized that intensified chemoimmunotherapy including systemic central nervous system (CNS) prophylaxis improves outcome and reduces the incidence of CNS-related events. Patients and methods: Inclusion criteria were age 18-65 years, primary diffuse large B-cell lymphoma or grade III follicular lymphoma without clinical signs of CNS disease and negative cerebrospinal fluid cytology, age-adjusted International Prognostic Index 2-3 and WHO performance score 0-3. Treatment consisted of six courses of R-CHOEP-14 followed by a course of high-dose cytarabine and a course of high-dose methotrexate. Primary end point was failure-free survival (FFS) at 3 years. Results: A total of 156 eligible patients with a median age of 54 years (range 20-64) were included. Three toxic deaths were observed. Three-year overall survival (OS) and FFS rates (median observation time 52 months for survivors) were 81% and 65%, respectively. Seven patients experienced CNS relapse, all within 6 months. Conclusions: The results are promising with favorable 3-year OS and FFS rates, a low toxic death rate and a lower than expected number of CNS events. CNS progression might be further reduced by earlier CNS prophylaxis. CinicalTrials.gov.identifier: NCT01502982.

Keywords
age-adjusted IPI, central nervous system, diffuse large B-cell lymphoma, intensive chemotherapy, prophylaxis
National Category
Cancer and Oncology
Identifiers
urn:nbn:se:umu:diva-71593 (URN)10.1093/annonc/mds621 (DOI)000318105000034 ()
Available from: 2013-06-05 Created: 2013-06-04 Last updated: 2018-06-08Bibliographically approved
Kimby, E., Östenstad, B., Brown, P. d., Holte, H. J., Hagberg, H., Erlanson, M., . . . Sundström, C. (2012). Rituximab (R) in Combination with Interferon-a2a (IFN) Versus Single R in Patients with Follicular or Other CD20+Low-Grade (indolent) Lymphoma. Final Results From a Randomized Phase III Study From the Nordic Lymphoma Group. Paper presented at 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), DEC 08-11, 2012, Atlanta, GA. Blood, 120(21)
Open this publication in new window or tab >>Rituximab (R) in Combination with Interferon-a2a (IFN) Versus Single R in Patients with Follicular or Other CD20+Low-Grade (indolent) Lymphoma. Final Results From a Randomized Phase III Study From the Nordic Lymphoma Group
Show others...
2012 (English)In: Blood, ISSN 0006-4971, E-ISSN 1528-0020, Vol. 120, no 21Article in journal, Meeting abstract (Other academic) Published
Place, publisher, year, edition, pages
American Society of Hematology, 2012
National Category
Hematology
Identifiers
urn:nbn:se:umu:diva-67072 (URN)000313838900165 ()
Conference
54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), DEC 08-11, 2012, Atlanta, GA
Available from: 2013-03-15 Created: 2013-03-12 Last updated: 2018-06-08Bibliographically approved
Organisations

Search in DiVA

Show all publications